Abstract
Extracorporeal membrane oxygenation (ECMO) is a selectively available therapeutic option, generally available in a large-size referral healthcare system. In a single-center experience of the use of venovenous ECMO for COVID-19 ARDS in a medium-size healthcare system during the pandemic, West et al. in their study have convincingly demonstrated that ECMO can become a broadly available therapeutic option without compromising quality.
